Please note that I said "potential buyers eyeing ARWR", I didn't included Roche and NVS as the have a priority for acquisition of ARWR. Thus, the buyers from the list vs Roche and Novartis will create an extremely aggressive bidding wars between them.
GILD bought Pharmasset Inc (a clinical-stage pharmaceutical company for the treatment of hepatitis C virus) for $11B.
Moreover, HBV has many times higher number of patients compared to HCV.
The competition to bring a multibillion-dollar drug new drug to market is fierce and as confirmed today at Jefferies by C. Anzalone ARWR is being “"a much as 2 years" ahead of competition Not to mention the recent failures of competition in this space!. Also, Not to mention AAT market!
Therefore, in my own very humble opinion, three potential buyers eyeing ARWR:
Merck & Co.,
Abbott Laboratories Less